SEATTLE, WA -- (Marketwired) -- 09/02/14 -- Atossa Genetics Inc. (NASDAQ: ATOS) today announced that its subsidiary, The National Reference Laboratory for Breast Health, Inc., or the NRLBH, will exhibit at the upcoming 2014 Breast Cancer Symposium in San Francisco, CA, September 4-6, 2014.
The NRLBH is certified under the Clinical Laboratory Improvement Amendments (CLIA), which regulates all laboratory testing performed on human samples under the Centers for Medicare and Medicaid Services. The premier testing facility is focused on breast health and development of innovative laboratory developed services and proprietary processes and procedures.
About the NRLBH and Atossa Genetics
Atossa Genetics Inc. is focused on improving breast health through the development of laboratory developed procedures, medical devices and therapeutics. The laboratory procedures are being developed by its subsidiary, the NRLBH. The laboratory services and the Company's medical devices are being developed so they can be used as companions to therapeutics to treat various breast health conditions. For additional information, please visit www.atossagenetics.com.
About the 2014 Breast Cancer Symposium
The Breast Cancer Symposium is a two-and-a-half-day educational forum that brings together medical oncologists, radiation oncologists, surgeons, and other members of the breast cancer treatment team to discover and discuss the latest research, with the goal of strengthening collaborative treatment approaches and enhancing patient care. Designed to facilitate cross-disciplinary learning, this year's meeting will provide a venue for interactive, case-based discussions with colleagues from all disciplines. For more information please visit http://breastcasym.org.
Forward-looking statements in this press release are subject to risks and uncertainties that may cause actual results to differ materially from the anticipated or estimated future results, including the risks and uncertainties detailed from time to time in Atossa's filings with the Securities and Exchange Commission, including without limitation its periodic reports on Form 10-K and 10-Q, each as amended and supplemented from time to time. Those risks and uncertainties include, for example, actions by the FDA, performance of commercial partners, and whether the NRLBH can commercialize its laboratory services in a timely and cost effective manner.